Frequently asked questions
Does the product come with instructions?
What's the actual amount in each vial?
Are additional supplies needed?
How long does a vial last?
KPV is a small tripeptide derived from the C-terminus of α-MSH that retains the parent hormone's anti-inflammatory activity while lacking melanotropic eects. Through PepT1 (peptide transporter 1) uptake in intestinal epithelial cells and macrophages, KPV directly accesses intracellular compartments where it inhibits NF-κB nuclear translocation and reduces expression of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and IL-8. Research models examine KPV's effects on inflammatory signaling cascades, intestinal epithelial barrier integrity through tight junction protein regulation, mucosal healing in colitis models, and antimicrobial properties in laboratory settings.
KPV has been extensively studied in inflammatory disease research, with investigations focusing on NF-κB pathway inhibition, intestinal inflammation models, epithelial barrier function, and immune modulation in various experimental systems. Studies examine both its unique transporter-mediated delivery and potent anti-inflammatory mechanisms.
Key Areas of Research:
• Inflammatory signaling: NF-κB inhibition, pro-inflammatory cytokine suppression (TNF-α, IL-1β, IL-6, IL-8), MAPK pathway modulation
• Intestinal inflammation: DSS and TNBS colitis model efficacy, mucosal healing promotion, inflammatory bowel disease pathways
• Barrier function: Tight junction protein upregulation (ZO-1, occludin, claudin-1), intestinal permeability reduction, epithelial integrity
• Immune modulation: Melanocortin receptor interactions (MC1R, MC3R), macrophage activation states, T-cell response regulation
Together, these investigations demonstrate KPV's multifaceted anti-inflammatory actions through PepT1-mediated uptake and direct intracellular signaling inhibition. As a minimal bioactive sequence, KPV provides a research framework for examining melanocortin-based anti-inflammatory mechanisms, intestinal immune regulation, and barrier function restoration in diverse inflammatory disease models.
Dalmasso et al., Gastroenterology, 2008
Brzoska et al., Inammation Research, 2008
Getting et al., Journal of Pharmacology and Experimental Therapeutics, 2003
